drugset
drugset / Trial / NCT05948059

Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy Subjects

NCT05948059 ↗

Phase 1 Completed 52 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase I clinical study with the primary objective of evaluating the safety and tolerability of SHR-2106 in healthy subjects after a single intravenous or subcutaneous administration.

Timeline

Start
2023-07-11
Primary completion
2024-05-10
Completion
2024-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-2106 Unknown 50 mg Intravenous
Subject SHR-2106 Unknown 300 mg Intravenous

Indications

No indication recorded.